GMiA welcomes TGA blueprint for reform
Australia’s Generic Medicines Industry Association (GMiA) says it welcomes the release last week of “A blueprint for TGA's future,” by the Parliamentary Secretary for Health and Ageing, Catherine King. This report, which was criticized by the branded medicines sector (The Pharma Letter December 8), is the government’s response to several major reviews of the Therapeutic Goods Administration (TGA) that have occurred over the last 18 months.
Kate Lynch, chief executive of the GMiA, said: “The various reviews have benefited from strong stakeholder consultation and GMiA endorses the commitment by government expressed in the TGA blueprint to continue with stakeholder consultation during the implementation of the agreed recommendations.”
Members of GMiA strongly support the government’s initiatives:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze